DOW JONES25,766.64-1190.95 -4.42%
S&P 5002,978.76-137.63 -4.42%
NASDAQ8,566.48-414.30 -4.61%

Mizuho Upgrades Nektar Therapeutics to Buy, Raises Price Target to $35

Mizuho analyst Difei Yang upgrades Nektar Therapeutics (NASDAQ:NKTR) from Neutral to Buy and raises the price target from $21 to $35.

Benzinga · 02/03/2020 10:34

Mizuho analyst Difei Yang upgrades Nektar Therapeutics (NASDAQ:NKTR) from Neutral to Buy and raises the price target from $21 to $35.